Clinical Trial

Stopping Pneumonia Antibiotherapy Regimen Early

Study acronym: SPARE
Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The hypothesis for this trial is that an antibiotic strategy for the management of non-severe community-acquired alveolar pneumonia in children aged 3 to 59 months, including amoxicillin 80-100 mg/kg/day for at least 3 days in case of rapid response and 5 days in case of delayed response, would not be inferior to current French recommendations (antibiotic therapy for 5 days in case of rapid response and 7 days in case of delayed response) in terms of treatment of failure rate at 7 days.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-02-26.
Trial Details
NCT Number NCT06291012
Lead Sponsor University Hospital, Montpellier
Collaborators: Direction Générale de l'Offre de Soins
Conditions Community-acquired Pneumonia, Child, Only
Enrollment 1,100 participants
Start Date 2024-09-01
Primary Completion 2027-05-01 (estimated)
Study Completion 2027-09-01 (estimated)
Updated on ClinicalTrials.gov 2024-05-20